Publications by authors named "N N Artamonova"
Background: Lu PSMA therapy is increasingly used for metastatic castration-resistant prostate cancer (mCRPC) treatment. However, data on its efficacy and safety in patients previously treated with Ra remain limited.
Methods: This retrospective, multicenter study evaluated 233 mCRPC patients treated with Lu PSMA at 5 European centers.
Impact of Renin-Angiotensin System Inhibitors on Disease Characteristics in Patients with Localized Prostate Cancer Treated with Radical Prostatectomy: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study.
Eur Urol Open Sci
November 2024
Background And Objective: Collagen biosynthesis is intricately involved in the development and progression of solid tumors. Renin-angiotensin system inhibitors (RASi) impede TGF-β-mediated collagen synthesis in tumors by hindering activation of the angiotensin receptor. Our aim was to investigate a potential association between RASi use and the aggressiveness of prostate cancer (PCa).
View Article and Find Full Text PDFProstate cancer (PCa) is the most prevalent malignancy and the second leading cause of cancer-related deaths among men. While adenocarcinoma of the prostate (adeno-PCa) is well-characterized, neuroendocrine prostate cancer (NEPC) remains poorly understood. Generally, NEPC is a rare but highly aggressive histological variant, however its limited patho-physiological understanding leads to insufficient treatment options associated with low survival rates for NEPC patients.
View Article and Find Full Text PDFBackground: Small cell neuroendocrine prostate cancer (SCNC) is a rare aggressive type of neuroendocrine prostate cancer (NEPC) characterized by aggressive clinical course and lack of response to hormone therapy.
Case Description: We present a case report of a 60-year-old man diagnosed with a histologically confirmed primary metastatic (bone, lymph nodes and visceral) SCNC with small components of an adenocarcinoma with clinical symptoms mimicking an acute prostatitis. Of note, serum based neuroendocrine markers (carcinoembryonic antigen, chromogranin A) were negative and the patient had a prostate-specific antigen (PSA) elevation.
Article Synopsis
- Two randomized trials have established that triplet therapy (androgen deprivation therapy, ARPI, and docetaxel) provides better survival rates compared to doublet therapy (ADT and docetaxel) for patients with metastatic hormone-sensitive prostate cancer.
- A real-world analysis involving 97 mHSPC patients from various Austrian centers was conducted, tracking treatment responses and clinical parameters, while certain guideline-based treatments were underutilized in a significant percentage of the patients.
- Findings showed that patients who started ARPI after chemotherapy had better treatment responses, while 61.9% experienced adverse events, yet all patients had a notable decline in PSA levels, indicating treatment effectiveness.